- Report
- August 2025
- 194 Pages
Global
From €3157EUR$3,545USD£2,748GBP
€3507EUR$3,939USD£3,053GBP
- Report
- October 2025
- 181 Pages
Global
From €3157EUR$3,545USD£2,748GBP
€3507EUR$3,939USD£3,053GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2671EUR$3,000USD£2,326GBP
- Report
- June 2025
- 150 Pages
Global
From €2403EUR$2,699USD£2,092GBP
- Report
- April 2025
- 137 Pages
Asia Pacific
From €3072EUR$3,450USD£2,674GBP
- Report
- April 2025
- 136 Pages
Africa, Middle East
From €3072EUR$3,450USD£2,674GBP
- Report
- May 2024
- 131 Pages
Global
From €5787EUR$6,499USD£5,038GBP
- Report
- May 2024
- 132 Pages
Global
From €5787EUR$6,499USD£5,038GBP
- Report
- October 2023
- 145 Pages
Global
From €2805EUR$3,150USD£2,442GBP
- Report
- April 2023
- 180 Pages
Global
From €2894EUR$3,250USD£2,519GBP
- Report
- May 2024
- 132 Pages
Global
From €5787EUR$6,499USD£5,038GBP
- Report
- August 2024
- 80 Pages
Japan
From €3116EUR$3,500USD£2,713GBP
- Report
- February 2024
- 360 Pages
Global
From €7079EUR$7,950USD£6,163GBP
- Report
- July 2024
- 150 Pages
Global
From €3962EUR$4,450USD£3,450GBP
- Report
- December 2023
- 140 Pages
Global
From €3962EUR$4,450USD£3,450GBP
- Report
- November 2020
- 199 Pages
Global
€4007EUR$4,500USD£3,488GBP
- Report
- October 2025
- 50 Pages
Global
From €2360EUR$2,650USD£2,054GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more